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1. Introduction 
In the last decades the need for novel diagnostic and chemotherapeutic tools became apparent. 
The increasing population and upcoming diverse disease patterns are leading to a synergistic 
effect, which emphasises the required demand for new types of pharmacological agents. 
Additionally, newly gained knowledge such as completing the human genome and on-going 
transcriptome and proteome projects identified novel targets for therapeutic intervention. 
However the upcoming number of diseases as well as their variety force medical science to 
accelerate the process of drug discovery by employing sophisticated methodologies for 
chemical synthesis of biological active compounds and time- and cost-sparing screening assays 
to develop novel drugs. These diseases are not only related to cancer or insights from the 
human genome project but become more prominent by time, since they are derived from 
human external sources such as infectious agents causing serious disease of mankind. For 
instance, approximately a quarter of the entire population is living in malaria endemic areas 
and is thereby daily exposed to lethal pathogens such as Plasmodium falciparum (WHO).  
Due to novel chemical synthesis procedures, approaches using combinatorial libraries 
followed by high-throughput screenings for biological activity are the current method of 
choice to increase the procession time and decrease application costs in the search for 
possible drug candidates. Subsequently possible drug targets are identified by in vitro 
assays, which test their biological relevance, and validated in animal models. Rational drug 
design, natural product or combinatorial library approaches have been employed to identify 
possible lead compounds for drug development. In order to compensate for the high 
demand of new drugs novel high-throughput strategies for screening high numbers of 
compounds were developed, which also decreased the production time (Fernandes, 1998). 
Most promising drug candidates are often subject to chemical modifications to improve 
their synthesis parameters as well as their toxicity profile and stability under physiological 
conditions. This procedure has been employed for several generations of drug development 
which were afterwards verified in animal models before clinical studies were applied (Faria 
and Ulrich, 2002, Majumder et al. 2009). The design of specific inhibitors against proteins 
involved in disease mediation is one of the primary objectives in pharmacological research. 
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The identification level of possible drug candidates for therapeutic applications has been 
increased by using a variety of screening strategies for active compounds in combinatorial 
libraries. In general, the suitability of combinatorial library approaches for drug design is 
based on the probability that a member of a high quantity population consisting of different 
molecules and structures, like peptides, carbohydrates and/or oligonucleotides, binds to the 
respective target of choice. For the discovery of specific ligands with binding capabilities to 
a desired target peptide- and oligonucleotide-based libraries were of particular interest since 
the library and thereby identified binders can be replicated by enzymatic catalysis. The 
SELEX technique (systematic evolution of ligands by exponential enrichment), was 
developed in parallel by Tuerk and Gold (1990) and Ellington and Szostak (1990) and is 
based on an oligonucleotide combinatorial library containing a vast number (around 1013) of 
different sequences and structural motifs for the in vitro selection of DNA or RNA molecules 
with binding specificity to their respective targets. The selected high affinity binders are 
called aptamers (from aptus (Latin) = to fit). Functional DNA or RNA molecules were 
identified as specific binders to a number of different targets including nucleotides 
(Sassanfar and Szostak, 1993, Meli et al., 2002), biologically active peptides and soluble 
proteins (Jellinek et al., 1993, Ruckman et al., 1998, Williams et al., 1996, Proske et al., 2002) 
and complex targets such as membrane-bound receptors (Ulrich et al. 1998) and blood 
vessels (Blank et al. 2001). However, due to degradation processes of nucleic acids in 
biological systems, aptamers were not ideal drug candidates. This limitation was overcome 
by chemical improvements in oligonucleotide synthesis which prolonged the stability of the 
molecules in biological tissues as well as their pharmacokinetics (Trujillo et al., 2007, Ni et 
al., 2011). New skills in oligonucleotide modification and lower synthesis costs extended the 
investigation of protein interactions from in vitro to in vivo applications and also the design 
of new compounds for pharmaceutical applications. The deriving aptamer properties are 
evoked by their respective tertiary structure providing unique features for these 
oligonucleotides to bind with nanomolar or even picomolar dissociation constants to their 
target proteins being higher than most of the natural occurring ligands or inhibitors. 
Moreover, aptamers possess numerous advantages over antibodies in many applications 
due to their non-peptide character and flexibility to interact with even to hidden targets 
with characteristics of small molecule binding. Further advantages of aptamers include the 
simplicity of synthesis and the ability of chemical modification of the nucleotides or 
backbones, their stability against thermal denaturation and nuclease degradation, the lack of 
immunogenicity and rapid penetration of tissues. Moreover, aptamers posses the ability to 
interact with functional protein domains such as ligand-binding domains mainly due to 
molecule-size advantages compared to antibodies or natural ligands (Ulrich et al., 2006). 
As already outline above aptamers can be subject to a variety of changes to enhance their 
stability especially for in vivo applications. These modifications can be introduced by using 
T7 RNA polymerase which accepts, for instance nucleotides like 2′-F-pyrimidines as 
substrates (Pestourie et al., 2005; Ulrich et al., 2006). By adding phosphorothioate based 
nucleotides to DNA- or 2′-F or 2′-amino-substitution of 2′OH groups of riboses to RNA-
libraries a nuclease resistant oligonucleotide library will be produced. 
In contrast to 2′-amino-pyrimidine substitution – 2’-fluoro-pyrimidine modifications lead to 
higher thermal stability (Aurup et al., 1994; Cummins et al., 1995) resulting in a theoretically 
increased affinity of aptamers to their targets (Eaton et al., 1995). In order to improve 
pharmacokinetics and the bioavailability, high molecular weight or/and lipophilic moieties 
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like polyethylene glycol are fused to the respective ends of the aptamers increasing 
aptamers’ half-life in plasma up to nine hours in contrast to a few minutes observed with 
unmodified aptamers (Willis et al., 1998). However, on the back site, aptamer applications 
face some diagnostic and/or pharmaceutical limitations in terms of their incapacity to pass 
biological membranes hindering intracellular aptamer applications (reviewed in Rimmele 
2003). 
 
 
 
Fig. 1. In vitro selection of aptamers as high-specificity binders to target cell epitopes. 
RNA or single-stranded (ss)-DNA-libraries for in vitro selection are obtained from a double-stranded 
DNA template containing a random region flanked by two constant sequences for PCR amplification 
(and in vitro transcription in case of RNA aptamers). Libraries are stabilized against nuclease activity by 
chemical modifications of the nucleotides. DNA or RNA libraries are generated by in vitro transcription 
or thermal denaturation followed by single-strand purification. The random oligonucleotide pool is 
exposed to its target cell (i.e. an erythrocyte expressing P. falciparum derived proteins on its cell surface), 
followed by elution of bound RNA/DNA molecules. Subsequently, these oligonucleotides are 
incubated with uninfected erythrocytes. All DNA/RNA molecules bound to these healthy cells are 
discarded, while unbound oligonucleotides are used for PCR amplification and generation of the DNA 
pool for the next selection cycle. The Cell SELEX process continues until the combinatorial 
oligonucleotide pool is purified to a homogeneous population binding with high affinity and specificity 
to their respective targets. Aptamers are identified by DNA sequencing and characterized for their 
binding affinities. Post-SELEX modifications are performed for optimization of aptamers for diagnostic 
and in vivo applications. 
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The modality of Cell SELEX, where aptamers are selected on the basis of binding to specific 
cell surface epitopes of disease cells, i.e. cancer cells or cells infected by pathogens (a 
positive selection step), followed by exposure of the library to a healthy somatic cell type, 
where all DNA/RNA molecules binding to common cell surface epitopes are discarded 
(negative selection step) has further broaden possible applications of the SELEX technique 
(see Figure 1 for details). The final library following various cycles of positive and  negative 
selection ideally contains one or more aptamers binding to differentially expressed cell 
surface markers. In many cases, these aptamers were able to detect a differential expression 
pattern on the cell surface, also named a molecular signature of the cells, not expressed by 
other cells. These features have made aptamers potent tools for targeting cancer cells and 
therapeutic agents for delivering a toxic load or an RNAi construct interfering with cancer 
cell replication or metabolism. The combination of improved synthesis protocols towards 
industrial scale and novel chemical modifications techniques was beneficial for the 
development of aptamer-based tools for diagnosis and therapy. We foresee that aptamers as 
nucleic acid based drugs will soon become of major pharmacological relevance in both, 
diagnostics and therapeutics. 
2. Applying the SELEX technique on protozoan parasites 
Parasite-caused diseases affect millions of people in the entire world. Parasitic infections are 
not only restricted to humans, they also play a major role in animal health. Just a few years 
ago infectious diseases were classified as an issue of the past. However, due to the 
increasing level of drug resistance of pathogens the need for new treatments or even more 
important  vaccines has become apparent. Unfortunately, these infectious diseases which are 
responsible for a level of mortality and morbidity are particular endemic in developing 
countries (Renslo and McKerrow, 2006). A variety of these parasitic diseases, including the 
so called neglected Chagas disease, leishmaniasis, sleeping sickness, schistosomiasis, 
elephantiasis, or onchocerciasis and of course malaria, are transmitted by vectors and, 
therefore, attempts to combat transmission vectors became prominent. Due to the 
continuously increasing human population and rising resistances of human pathogenic 
agents towards current treatment, there is an urgent need for novel diagnostic and 
therapeutic tools to tackle the foreseeable problems of the next generation. High attention is 
not only drawn to the development of new tools and their fast application but also to the 
commercial value in terms of their maintaining and application costs. In this chapter we 
summarize the current status of SELEX applications in human infectious diseases caused by 
protozoan pathogens.  
3. SELEX applications in Leishmaniasis 
The sandflies of the Phlebotomus genus are responsible for the transmission of the protozoan 
flagellate Leishmania. Infection with this parasite causes leishmaniasis, which can cause 
death in the absence of treatment. Specially, visceral leishmaniasis (kala azar), caused by L. 
donovani/infantum infection, is responsible for a high level of mortality if untreated. Muco-
cutaneous leishmaniasis (L. braziliensis infection) or cutaneous leishmaniasis (L. 
major/mexicana infection) are not considered to be lethal, however the latter can result in 
unaesthetic stigmata (Herwaldt, 1999). The major intention of the treatment is prevention 
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from death after infection by L. donovani. Due to this high potency the antimonials 
Pentostam® and Glucantime® were the therapeutics of choice for antileishmanial therapy 
since decades. However, these drugs revealed a number of disadvantages in terms of their 
mode of administration, the long duration of treatment, the high cost and the serious side 
effects. Therefore, the traditional drugs Amphotericin B and pentamidine were resurrected 
although they are known for causing irreversible toxic effects. However, new formulations 
and adapted dosages made these drugs applicable (Berman, 1997, Berman, 1999). The first 
oral drug, miltefosine was introduced by the Indian government for treatment of visceral 
leishmaniasis in 2002. Despite cure rates of up to 98% (Roberts, 2005, Berman, 2008), the 
drug also evokes serious side effects such as vomiting, diarrhea and can cause 
abnormalities. In order to discover novel therapeutics to tackle leishmaniasis without such 
serious side effects, the SELEX technology has been applied on the parasite L. infantum 
which is responsible for the most severe visceral leishmaniasis. Gonzales and co-workers 
were focussing on peculiarities such as gene expression and organisation in Leishmania 
(Ramos et al., 2007 and 2010). Leishmania does not condense its chromatin during mitosis 
which might be caused by the respective histones. Although histones are extremely 
conserved proteins in all livestock, high sequence divergences have been identified in the N- 
and C-terminal protein regions as targets for diagnostic and/or therapeutic intervention. 
Ramos et al. developed aptamers against the recombinantly expressed histone antigens H2A 
and H3 and even, despite of the sequence homology of histone proteins, the generated 
aptamers were highly selective for the parasite proteins. Aptamers were also directed 
against the L. infantum kinetoplastid membrane protein-11 (KMP-11) which is a major 
component of the cell membrane of kinetoplastid parasites (Moreno et al., 2003). Since KMP-
11 is a cytoskeleton-associated protein it is believed that its function lies in mobility or is 
related to the flagellar structure. The SELEX technique has also been employed in gaining 
cellular knowledge on how the tRNA import into the mitochondrion of L. tropica is achieved 
(Bhattacharyya et al., 2002). However, approaches towards the development of therapeutic 
have yet to be carried out due to missing biological activity of the selected aptamers or 
difficulties in accessing target proteins. Therefore, current applications of aptamers to 
Leishmania are mainly restricted investigative or diagnostic tools. 
4. SELEX applications towards treatment of Trypanosoma infections 
In the last century infectious diseases caused by the tropical protozoan parasites 
Trypanosoma became more prominent due to their medical importance. Infections are caused 
by the pathogens Trypanosoma cruzi, the causative agent of Chagas’ disease occurring in 
Latin America, and T. brucei ssp., the African trypanosomes, which are responsible for 
sleeping sickness and Nagana in cattle. These infectious diseases are accountable for 
relevant health and socioeconomic problems in endemic countries such as Latin America, 
sub-Saharan Africa, and tropical and other subtropical areas in Africa and America. The 
current medication is known for its toxicity, poor activity in immune-suppressed patients 
and long term treatment combined with high costs. Moreover, vaccines are not foreseeable 
in the near future. Therefore, the current treatment is just relying on chemotherapeutics. The 
treatment of Chagas’ disease is based on two nitroheterocyclic drugs, nifurtimox and 
benznidazole, which are administered as pro-drugs and become intracellularly activated. 
However, both drugs occasionally reveal serious side effects, but no other compound is near 
preclinical or clinical development for the treatment of Chagas´ disease. The human African 
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trypanosomiasis (also called sleeping sickness) is caused by T. brucei, which is transmitted to 
humans by infected Tsetse flies. Human sleeping sickness is triggered by two sub-species T. 
b. rhodesiense is responsible for acute infections and T. b. gambiense leading to more chronic 
infections. The parasites proliferate in the lymph, blood as well as in peripheral organs and 
invade the central nervous system, instigating serious neurological disorders (Barrett et al., 
2003). 
Without treatment the disease is lethal. In the human host, African trypanosomes sustain 
extracellularly and face the exposure to the human immune system. The parasites 
circumvent the human immune response mainly by antigenic variation of their variant 
surface glycoprotein coat (VSG) (Vickerman, 1978). However, the parasite also displays 
invariant surface proteins, but they are inaccessible to the host’s immune response. 
Prior to infesting the central nervous system by the parasites, medication is carried out 
with suramin and pentamidine against the rhodesiense and gambiense forms of the disease, 
respectively. Afterwards first-line treatment is mediated by melarsoprol, although the 
drug often induces serious, sometimes fatal side effects. Originally developed for cancer 
chemotherapy, eflornithine was also effective against the gambiense form. Eflornithine is 
an inhibitor of the ornithine descarboxylase (ODC) leading to a depletion of the parasites’ 
polyamine levels (Docampo and Moreno, 2003). Interestingly, the drug shows similar 
affinity to both the mammalian and parasite’s enzymes; however the trypanosomal ODC 
has a shorter half-life than its mammalian counterpart which makes the parasite’s 
metabolism more susceptible resulting in growth arrested. The parasite does not 
differentiate into the non-dividing stumpy forms and become sensitive to host immune 
system, since these forms are not able to undergo antigenic variation of their VSG (Wang, 
1995). Surface proteins, such as the VSG coat of the African trypanosomes, were also 
targeted by aptamers. Three aptamer families were isolated with binding affinities in the 
nanomolar and subnanomolar range (Lorger et al., 2003). Since RNA aptamers are subject 
to rapid degradation in serum they need to be modified in order to prolong their half-life 
from a few seconds to several hours (Ulrich et al. 2004). Chemical modification of the anti-T. 
brucei aptamer led to nuclease resistance (Lorger et al., 2003). However, as per definition the 
VSG coat is variable and thereby modified by the parasite in time to escape the immune 
response of the human host, attention was drawn to other surface proteins of T. brucei. In 
particular, invariant surface glycoproteins (ISGs), which comprise receptor complexes and 
transporters (Overath et al., 1994), were targeted by RNA aptamers using a combinatorial 
selection process on live trypanosomes. The selected RNA aptamers bound to a single 42 
kDa protein located within the flagellar pocket of the parasite which might be ESAG 7, a 
transferrin receptor subunit (Homann and Goringer, 1999). These results were very 
promising since the aptamer bound to an invariant trypanosomal surface protein enabling 
the selective targeting of the non VSG coat. Even further, Homann and Goringer could 
demonstrate that at increased temperature, the terminal ends of the aptamer were degraded 
and became rapidly engulfed into the parasite and incorporated into the lysosome by 
vesicular transportation. Proof-of principle experiments were carried out with biotin 
labelled aptamers which were visualized by immune fluorescence microscopy using anti-
biotin antibodies (Goringer et al., 2003). The obtained results demonstrate that the specific 
RNAs could be exploited as so called 'piggy backs' molecules to traffic aptamer-coupled 
drugs into the lysosomal compartment of the parasite. Such aptamers might have the 
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potential to act as novel drugs against African trypanosomiasis. SELEX applications were 
not only restricted to T. brucei; this technology was also applied on American 
trypanosomiasis caused by T. cruzi. As already outlined the causing agent of Chagas' 
disease depends on invasion of host cells to complete its life cycle. Thereby the parasite 
needs to build up parasite-host cell adhesion for initiation of the invasion process (Alves 
and Colli, 2008). Macromolecules on host cell surfaces such as laminin, thrombospondin, 
heparan sulfate, and fibronectin are believed to be involved in parasite-host cell contact 
(Ulrich et al., 2002, Simmons et al., 2006). Approaches have been undertaken to selectively 
interfere with parasite host cell receptors in order to inhibit the cellular invasion process of 
T. cruzi. The SELEX technology was employed to evolve nuclease-resistant RNA aptamers 
which block in vitro receptor-ligand interactions between T. cruzi trypomastigotes and 
epithelial monkey kidney LLC-MK(2) cells and thereby partially inhibit cell invasion by the 
parasite (Ulrich et al., 2002). Aptamers were identified with binding affinities in the 
nanomolar range to parasite receptors expressed by infective trypomastigote and not by 
insect epimastigote forms for the host cell matrix molecules fibronectin, heparan sulphate, 
laminin and thrombospondin (Ulrich et al., 2002; Alves and Colli, 2008). Reduction in the 
infection rate in vitro of up to 70 percent was observed at a low micromolar aptamer 
concentration. 
5. SELEX approaches have also been undertaken to other protozoan 
parasites such as the malaria pathogens 
The parasitic disease malaria represents one of the most serious threats to human health 
worldwide with an enormous impact on the mortality and morbidity, especially in sub-
Saharan Africa. More than 2000 million people are exposed to the infection with malaria 
leading to estimated 500 million clinical cases and more than one million deaths per annum; 
mostly young children in Africa. A vaccine is not available and the control of the disease 
depends solely on the administration of a small number of drugs. Malaria is presently 
undergoing resurgence and the fight against Plasmodium falciparum -the most virulent 
species accounting for over 90% of deaths- has become a significant problem (Greenwood et 
al., 2008). Due to the high mutational rate of the parasite and its resulting rapid adaptation 
to environmental changes, its drug resistance and geographic distribution are increasing. 
Further aspects such as socio-economic factors, increasing migration patterns, failing health 
care systems and the rapid development and dispersal of the respective insecticide resistant 
forms of the mosquito vector are contributing to the problem. Currently, only one drug, 
Artemesinin, is still effective against the malaria parasite. However, the first evidence of 
drug resistance against Artemisinin and combinations has been reported at the 
Cambodian/Thailand border from where resistance against the most cost-effective drug, 
chloroquine, has also spread to the rest of the world (Wangroongsarb et al., 2011). Therefore 
continuous discovery and development of new drugs are urgently needed. In the past the 
discovery of novel antimalarials was mainly directed towards chemotherapeutic 
interventions and vaccines (Alonso et al., 2011). As far as drugs are concerned, major focus 
was drawn on the peculiarities occurring in the malaria parasite such as the folate 
metabolism, haemoglobin degradation and subsequently the polymerisation of heme into 
the chemically inert “malaria” pigment, hemozoin. Chloroquine is believed to interfere with 
the heme detoxifying biochemical pathway which leads to parasites’ death. In a recent 
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report aptamers were used to prevent hemozoin formation in a proof-of-concept study to 
demonstrate that oligonucleotide-based drugs are exploitable to modulate essential 
biochemical pathways in P. falciparum (Niles et al., 2009). Indeed hemozoin formation was 
significantly inhibited by heme-binding aptamers in parasite extract. Even further, a 
growth inhibitory effect could be shown in aptamer preloaded human erythrocytes (Niles 
et al., 2009). However, in vivo assays have yet not been performed in order to evaluate 
whether these aptamers are also applicable as drugs. In another approach RNA aptamers 
were generated binding to the major parasite derived surface protein embedded in the 
erythrocytic membrane – the var-gene encoded P. falciparum erythrocyte membrane protein 
1 (PfEMP1) (Barfod et al., 2009). PfEMP1 is involved in cytoadherance to human cells, such 
as endothelial cells of blood vessels or  in spontaneous binding of uninfected erythrocytes to 
P. falciparum-infected red blood cells (rosetting). The secretion of this protein is proposed to 
accentuate the symptoms of malaria by preventing the clearance of infected erythrocytes 
in the spleen (Buffet et al., 2011). While doing so the parasite would become susceptible to 
the human immune system. However the genome of the parasite encodes about 60 var-
genes and the parasite is able to switch expression to another gene of this family, leading to 
a different PfEMP1 protein. Due to antigenic variation the parasite can avoid interference 
with the host immune response (Flick and Chen, 2004). Recently, Barfod and co-workers 
selected aptamers against the recombinantly expressed N-terminal DUFFY-binding like 
domain (DBL1a) of the PfEMP1 protein. Subsequently, the isolated aptamers were tested on 
cellular level by screening against populations of infected and non-infected erythrocytes 
(Barfod et al., 2009). The set of biological active aptamers inhibited the rosetting progress 
which is indicative for the functionality of the RNA ligands and promising for further 
evaluation of their activity in vivo. 
6. Conclusion 
Aptamers are able to identify individual epitopes within a complex mixture of potential 
targets and can also be used for ligand-mediated target purification (Nery et al., 2009, Ulrich 
and Wrenger, 2009). It has been demonstrated that aptamers evolved against human 
membrane proteins bind specifically to previously unidentified target proteins (Morris et al., 
1998). The same methodology (deconvolution SELEX) was used to stain rat brain tumor 
vessels and identify the endothelial regulatory protein pigpen as aptamer-target protein 
(Blank et al., 2001). These works resulted in the conclusion that each cell type differs from 
others by its molecular signature exposed on the cell surface. The fact that aptamers can 
distinguish between small differences in the molecular signature of cell-surface antigens 
emphasizes the feasibility of the chosen technology. Even further  highly specific aptamers 
distinguishing between host cell proteins are capable to selectively bind and thereby 
interfere with parasite-derived proteins in order to stop proliferation of these deadly human 
parasites.  
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